Destaques regulatrios: Diversos agonistas de GLP-1 j esto aprovados pela Anvisa , com indicao para diabetes tipo 2 Em 2023, a Anvisa aprovou a semaglutida injetvel (nome comercial Wegovy) para obesidade Algumas verses esto disponveis no SUS via Protocolos Clnicos e Diretrizes Teraputicas (PCDTs) , mas com critrios restritivos O uso para emagrecimento ainda foco de debates sobre judicializao e prescrio racional Riscos, efeitos adversos e controvrsias Apesar dos benefcios teraputicos significativos, os medicamentos base de GLP-1 no esto isentos de efeitos colaterais e desafios clnicos
With the Medicines Amendment Bill streamlining approvals, the door is opening for repurposed therapies to enter the NZ pipeline faster
In animal studies, compounded semaglutide caused thyroid C-cell tumors
by contrast, antagonizing NMDA receptors in the hypothalamus has been linked to a reduction in food intake and a decrease in body weight 8
Published RNA-seq data of mouse and human alpha and beta cells indicate that expression levels of Gcgr/GCGR are much lower in alpha cells than in beta cells [36, 37]